TSHR
Thyrotropin receptor
Also known as: LGR3, TSHR_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P16473
- Gene
- TSHR
- Ensembl
- ENSG00000165409
- Chromosome
- 14
- Canonical length
- 764 aa
- Protein class
- Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins
- Secretome location
- Intracellular and membrane
OverviewNCBI Gene
The protein encoded by this gene is a membrane protein and a major controller of thyroid cell metabolism. The encoded protein is a receptor for thyrothropin and thyrostimulin, and its activity is mediated by adenylate cyclase. Defects in this gene are a cause of several types of hyperthyroidism. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2008]
Canonical amino-acid sequenceUniProt
764 residues, UniProt reviewed canonical sequence.
>P16473|TSHR
1 MRPADLLQLV LLLDLPRDLG GMGCSSPPCE CHQEEDFRVT CKDIQRIPSL PPSTQTLKLI
61 ETHLRTIPSH AFSNLPNISR IYVSIDVTLQ QLESHSFYNL SKVTHIEIRN TRNLTYIDPD
121 ALKELPLLKF LGIFNTGLKM FPDLTKVYST DIFFILEITD NPYMTSIPVN AFQGLCNETL
181 TLKLYNNGFT SVQGYAFNGT KLDAVYLNKN KYLTVIDKDA FGGVYSGPSL LDVSQTSVTA
241 LPSKGLEHLK ELIARNTWTL KKLPLSLSFL HLTRADLSYP SHCCAFKNQK KIRGILESLM
301 CNESSMQSLR QRKSVNALNS PLHQEYEENL GDSIVGYKEK SKFQDTHNNA HYYVFFEEQE
361 DEIIGFGQEL KNPQEETLQA FDSHYDYTIC GDSEDMVCTP KSDEFNPCED IMGYKFLRIV
421 VWFVSLLALL GNVFVLLILL TSHYKLNVPR FLMCNLAFAD FCMGMYLLLI ASVDLYTHSE
481 YYNHAIDWQT GPGCNTAGFF TVFASELSVY TLTVITLERW YAITFAMRLD RKIRLRHACA
541 IMVGGWVCCF LLALLPLVGI SSYAKVSICL PMDTETPLAL AYIVFVLTLN IVAFVIVCCC
601 YVKIYITVRN PQYNPGDKDT KIAKRMAVLI FTDFICMAPI SFYALSAILN KPLITVSNSK
661 ILLVLFYPLN SCANPFLYAI FTKAFQRDVF ILLSKFGICK RQAQAYRGQR VPPKNSTDIQ
721 VQKVTHEMRQ GLHNMEDVYE LIENSHLTPK KQGQISEEYM QTVLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TSHR can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.35
- Highest tissue expression
- 257 nTPM
Expression across tissuesHPA
Tissue
- thyroid gland: 257 nTPM
- thymus: 19 nTPM
- retina: 2 nTPM
- lymph node: 1.8 nTPM
- bone marrow: 1 nTPM
- fallopian tube: 1 nTPM
Single-cell type
- cardiomyocytes: 176 nCPM
- epicardial cells: 148 nCPM
- salivary acinar cells: 96 nCPM
- fibro-adipogenic progenitors: 90 nCPM
- plasma cells: 76 nCPM
- adipocytes: 60 nCPM
Immune cell
- T-reg: 6.9 nTPM
- naive B-cell: 1.7 nTPM
- neutrophil: 0.8 nTPM
- memory B-cell: 0.6 nTPM
- basophil: 0.5 nTPM
- memory CD4 T-cell: 0.5 nTPM
Brain region
- cerebellum: 26 nTPM
- cerebral cortex: 22 nTPM
- basal ganglia: 21 nTPM
- white matter: 21 nTPM
- medulla oblongata: 21 nTPM
- hypothalamus: 20 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about TSHR.
Disease | AllUniProt
Conditions TSHR is implicated in, by any mechanism.
- Hypothyroidism, congenital, non-goitrous, 1 (CHNG1) MIM:275200
- Familial gestational hyperthyroidism (HTFG) MIM:603373
- Hyperthyroidism, non-autoimmune (HTNA) MIM:609152
Disease | GeneticClinVar
109 pathogenic / likely-pathogenic of 622 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Hypothyroidism due to TSH receptor mutations
- Familial hyperthyroidism due to mutations in TSH receptor
- Familial gestational hyperthyroidism
- TSHR-related disorder
- Ovarian cancer
Disease | ImmuneIEDB
Conditions an epitope on TSHR was assayed in.
- Graves' disease B and T cell
- autoimmune thyroiditis B and T cell
- nodular goiter T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against TSHR are reported. Each links to that disease's full target list.
- Graves Disease 824
- Thyroiditis, Autoimmune 154
- Hyperthyroidism 149
- Hypothyroidism 116
- Hashimoto Disease 55
- Thyroiditis 23
- Diabetes Mellitus, Type 1 10
- Hepatitis C 7
- Arthritis, Rheumatoid 5
- COVID-19 5
- Hepatitis C, Chronic 5
- HIV Infections 5
- Lupus Erythematosus, Systemic 5
- Abortion, Spontaneous 4
- Celiac Disease 4
- Urticaria 4
- Myasthenia Gravis 3
- Pre-Eclampsia 3
- Sjogren's Syndrome 3
Showing 19 of 40 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for TSHR from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1,344 publications
- Molecular Mechanisms in Autoimmune Thyroid Disease.
2023 · Cells · RCR 20.4 · 145 citations - Graves' disease.
2020 · Nat Rev Dis Primers · RCR 18.8 · 314 citations - Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
2024 · Thyroid · RCR 17.2 · 56 citations - Autoantibodies to the thyrotropin receptor.
1988 · Endocr Rev · RCR 16 · 539 citations - Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment.
2024 · Int J Mol Sci · RCR 15.5 · 58 citations
Show 20 more of 1,344 total
- Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases.
2017 · Front Immunol · RCR 14.7 · 309 citations - Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease.
2006 · J Clin Endocrinol Metab · RCR 10.6 · 344 citations - TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
2008 · Eur J Endocrinol · RCR 10.3 · 304 citations - Management of Graves Thyroidal and Extrathyroidal Disease: An Update.
2020 · J Clin Endocrinol Metab · RCR 9.4 · 143 citations - A receptor assay for the measurement of TSH receptor antibodies in unextracted serum.
1984 · Clin Endocrinol (Oxf) · RCR 9.1 · 211 citations - Pathogenesis of thyroid eye disease: review and update on molecular mechanisms.
2016 · Br J Ophthalmol · RCR 8.9 · 191 citations - Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease.
1999 · J Clin Endocrinol Metab · RCR 7.7 · 236 citations - Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.
2023 · J Clin Endocrinol Metab · RCR 7.6 · 51 citations - TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-Results from a phase I clinical trial.
2022 · Clin Endocrinol (Oxf) · RCR 7.6 · 67 citations - The thyrotropin receptor 25 years after its discovery: new insight after its molecular cloning.
1992 · Mol Endocrinol · RCR 7 · 244 citations - A 2013 European survey of clinical practice patterns in the management of Graves' disease.
2016 · Clin Endocrinol (Oxf) · RCR 6.9 · 136 citations - Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease.
1989 · Acta Endocrinol (Copenh) · RCR 6.7 · 170 citations - Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
2000 · Clin Endocrinol (Oxf) · RCR 6.5 · 223 citations - Clinical review: Clinical utility of TSH receptor antibodies.
2013 · J Clin Endocrinol Metab · RCR 6.5 · 157 citations - Diagnosis and classification of Graves' disease.
2014 · Autoimmun Rev · RCR 6.5 · 163 citations - Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens.
2003 · Ann Intern Med · RCR 6.3 · 230 citations - Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
2021 · J Endocrinol Invest · RCR 6.1 · 64 citations - Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies.
1992 · Thyroid · RCR 6.1 · 162 citations - Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
2013 · Thyroid · RCR 6.1 · 160 citations - TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY.
2020 · Endocr Pract · RCR 5.9 · 79 citations
Reference: B cellIEDB
8 publications
- Prokaryotic expression of the thyrotropin receptor and identification of an immunogenic region of the protein using synthetic peptides.
1991 · Biochem Biophys Res Commun · RCR 2 · 78 citations - Identification of epitopes and affinity purification of thyroid stimulating auto-antibodies using synthetic human TSH receptor peptides.
1994 · Autoimmunity · RCR 1 · 36 citations - Graves' IgG recognizes linear epitopes in the human thyrotropin receptor.
1992 · Biochem Biophys Res Commun · RCR 1 · 31 citations - Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease.
2009 · J Clin Endocrinol Metab · RCR 0.9 · 38 citations - Presence of heterogeneous thyroid-stimulating antibodies in sera from individual Graves' patients as shown by synthesized thyrotropin receptor peptide application: evidence showing two independent epitopes and a possible recognition of two epitopic regions by one antibody molecule.
1995 · Eur J Endocrinol · RCR 0.7 · 23 citations
Show 3 more
- Heterogeneity in cellular and antibody responses against thyrotropin receptor in patients with Graves' disease detected using synthetic peptides.
1993 · J Autoimmun · RCR 0.3 · 11 citations - Identification of thyroid blocking antibodies and receptor epitopes in autoimmune hypothyroidism by affinity purification using synthetic TSH receptor peptides.
1995 · Autoimmunity · RCR 0.3 · 9 citations - Epitope mapping of a recombinant human TSH receptor extracellular domain: identification of a predominant epitope using animal sera.
1996 · J Clin Lab Anal · RCR 0.1 · 3 citations
Reference: T cellIEDB
10 publications
- Immunotherapy With Apitopes Blocks the Immune Response to TSH Receptor in HLA-DR Transgenic Mice.
2018 · Endocrinology · RCR 1.7 · 39 citations - T-cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain.
1995 · J Clin Endocrinol Metab · RCR 1.1 · 42 citations - Proliferative responses of peripheral blood mononuclear cells from patients with Graves' disease to synthetic peptides epitopes of human thyrotropin receptor.
1994 · Thyroid · RCR 0.7 · 25 citations - Detection of major T cell epitopes on human thyroid stimulating hormone receptor by overriding immune heterogeneity in patients with Graves' disease.
1997 · J Clin Endocrinol Metab · RCR 0.6 · 25 citations - TSH receptor sequences recognized by CD4+ T cells in Graves' disease patients and healthy controls.
1995 · J Autoimmun · RCR 0.3 · 14 citations
Show 5 more
- Identification of novel HLA-A0201-restricted T-cell epitopes against thyroid antigens in autoimmune thyroid diseases.
2020 · Endocrine · RCR 0.3 · 5 citations - Thyroid specific T helper cell analysis by ELISPOT assay with thyrotropin receptor (TSH-R) peptides.
2002 · Peptides · RCR 0.3 · 8 citations - Thyrotropin receptor T cell epitopes in autoimmune thyroid disease.
1995 · Clin Immunol Immunopathol · RCR 0.3 · 12 citations - T-cell recognition of residue 158-176 in thyrotropin receptor confers risk for development of thyroid autoimmunity in siblings in a family with Graves' disease.
1996 · Thyroid · RCR 0.3 · 10 citations - High frequency of T-cell lines responsive to immunodominant epitopes of thyrotropin receptor in healthy subjects.
1998 · Thyroid · RCR 0.2 · 8 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.26
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.33
- DepMap mean gene effect
- 0.16
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adenylate cyclase-activating G protein-coupled receptor signaling pathway
- cell surface receptor signaling pathway
- cell-cell signaling
- cellular response to glycoprotein
- G protein-coupled receptor signaling pathway
- G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
- hormone-mediated signaling pathway
- positive regulation of cell population proliferation
- positive regulation of cold-induced thermogenesis
- cellular response to thyrotropin-releasing hormone
- thyroid-stimulating hormone signaling pathway
Molecular functions
- G protein-coupled peptide receptor activity
- G protein-coupled receptor activity
- protein-containing complex binding
- signaling receptor activity
- thyroid-stimulating hormone receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TSHR in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TSHR as an antibody target. Whether an autoantibody or antibody against TSHR could matter depends on whether native TSHR is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TSHR is annotated at the cell surface, where native TSHR is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TSHR as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...